Research programme: CCR5 antagonists - Takeda

Drug Profile

Research programme: CCR5 antagonists - Takeda

Alternative Names: TAK-779

Latest Information Update: 14 Mar 2007

Price : $50

At a glance

  • Originator Takeda
  • Class Small molecules
  • Mechanism of Action CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 31 Mar 2003 Preclinical trials in HIV infections treatment in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top